66th ASH Annual Meeting: 603. Lymphoid Oncogenesis: Basic: Poster III

Symposia: Lymphoid Oncogenesis: Basic Oral and Poster Abstracts
Poster

Research, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, AML, Fundamental Science, Apoptosis, Lymphomas, Non-Hodgkin lymphoma, Translational Research, Genetic Disorders, Genomics, Plasma Cell Disorders, LGL, B Cell lymphoma, Hematopoiesis, T Cell lymphoma, Diseases, Immune mechanism, Cell expansion, Immunology, Lymphoid Malignancies, Metabolism, Biological Processes, Myeloid Malignancies, Technology and Procedures, Gene editing, Molecular biology, Profiling, Pathogenesis, Animal model, Omics technologies, Pathology

Halls G-H (San Diego Convention Center)

4120

Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and De Novo Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications

Johnvesly Basappa, PhD¹^*, Aaron Goldman, PhD²^*, Cosimo Lobello, PhD³^*, Shengchun Wang, PhD¹^*, David Rushmore, BS³^*, Pin Lu, MD, Ph.D.¹^*, Reza Nejati, MD³ and Mariusz Wasik, MD¹^*

¹Fox Chase Cancer Center, Philadelphia, PA
²Wistar Institute, Philadelphia, PA
³Fox Chase Cancer Center, PHILADELPHIA, PA

4121

A Novel Form of AEBP2-Containing PRC2.2 Is a Genetic Dependency in Germinal Centre B-Cell Lymphoma and Its Targeting Can Overcome Acquired Resistance to EZH2 Inhibition

James Nolan, MB, PhD¹, Daniel Angelov, MSc, MB¹, Darragh Nimmo, BSc¹^*, Gráinne Holland, MSc¹^*, Molly Davies, BSc²^*, Eugene Dillon, PhD²^*, David Reck, BA¹^*, Craig Monger, PhD¹^*, Chun-Wei David Chen, PhD³, Gerard L Brien, PhD^4,5^*, Elisabeth Vandenberghe, MD, PhD⁶^*, Eric Conway, PhD²^* and Adrian Bracken, PhD¹^*

¹Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland
²School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland
³Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA
⁴Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom
⁵MRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom
⁶Department of Haematology, St James' Hospital, Dublin, Ireland

4122

Identification of Transcriptional Targets of NSD2 and the Underlying Regulatory Mechanism in t(4;14) Multiple Myeloma Cells Using the Slam-Seq and d-TAG Technologies

Yubao Wang, PhD¹^*, Sanxiong Liu, PhD²^*, Hussein Ghamlouch, PhD³^*, Faith E Davies, MD² and Gareth Morgan, M.D., Ph.D.²^*

¹Perlmutter Cancer Center, Multiple Myeloma Research Program, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
²Perlmutter Cancer Center, Multiple Myeloma Research Program, NYU Langone Health, New York, NY
³Hematology and Cell Therapy, CHU Amiens-Picardie, Amiens, France

4123

Unraveling Metabolic Dependencies and Molecular Mechanisms in CNS ALL: The Role of MiR-181a and VEGF

Tommaso Gianferri^*, Teresa Mack^*, Daniel Tews, PhD^*, Klaus-Michael Debatin, MD, Professor, Lüder Hinrich Meyer, MD, Professor^* and Vera Münch, PhD^*

Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany

4124

Dissecting Mechanistic Differences between EZH2 Gain-of-Function Events in Non-Hodgkin B Cell Lymphomas

Sofia R Smith, BS^1,2^* and George P Souroullas, PhD^1,3,4

¹Division of Oncology, Washington University in St. Louis, St. Louis, MO
²Department of Medicine, Washington University in St. Louis, Saint Louis, MO
³Department of Medicine, Washington University in St. Louis, St. Louis, MO
⁴Siteman Comprehensive Cancer Center, Washington University in St. Louis, St. Louis, MO

4125

Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies

Kadriye Nehir Cosgun, PhD¹^*, Mark E Robinson, PhD¹^*, Nikol Agadzhanian, MSc¹^*, Zhangliang Cheng, BSc¹^*, Salim Oulghazi, MD¹^*, Philipp Berning, MD¹^*, David Fonseca-Arce¹^*, Kohei Kume, PhD¹^*, Jake Fontaine¹^*, Lai N Chan, PhD¹, Jaewoong Lee, PhD^1,2^*, Fang Yu, PhD³^*, Zhijian Qian⁴, Joo Y. Song, MD⁵, Wing Chung Chan, MD⁵, Jianjun Chen, PhD⁶, Mark M Taketo⁷^*, Hilde Schjerven, PhD⁸^* and Markus Müschen, MD¹

¹Center of Molecular and Cellular Oncology, Yale University, New Haven, CT
²School of Biosystems and Biomedical Sciences, Korea University, Seoul, Korea, Republic of (South)
³Division of Hematology/Oncology, Department of Medicine and Department of Biochemistry and Molecular Biology, The University of Florida, Gainesville, FL
⁴Division of Hematology/Oncology, Department of Medicine and Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL
⁵Department of Systems Biology, City of Hope Comprehensive Cancer Center, Duarte, CA
⁶City of Hope Comprehensive Cancer Center, Duarte, CA
⁷Graduate School of Medicine, Kyoto University, Kyoto, JPN
⁸Department of Laboratory Medicine and Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA

4126

The Hypomethylating Agent 5-Aza-4’-Thio-2’-Deoxycytidine Targets Early B Progenitor Cells and Leads to B Cell Precursor Acute Lymphoblastic Leukemia in Rag1 Knockout Mice

Vijay Negi, PhD^*, Ryan Bertoli, BS^*, Emily Muenzer^* and Peter D. Aplan, MD

Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

4127

Mapping the Dynamic DNA Methylation Landscape in Pre-B ALL from Diagnosis to Relapse Reveals a Role for Aberrant PRC2 Regulation

Athanasia Liapodimitri^1,2^*, Oscar Camacho²^*, Kayleigh Lunsford^2,3^*, Ashley R Tetens^2,3^*, Jordyn Craig-Schwartz^2,3^*, Kegan Skalitzky^2,3^*, Karen R Rabin, MD, PhD^4,5,6, Andy Feinberg, MD, MPH²^* and Michael Koldobskiy, MD, PhD^2,3^*

¹Pediatric Oncology, Sidney Kimmel Comprehensive Cancer, Johns Hopkins University School of Medicine, BALTIMORE, MD
²Center for Epigenetics, Johns Hopkins University School of Medicine, Baltimore, MD
³Pediatric Oncology, Sidney Kimmel Comprehensive Cancer, Johns Hopkins University School of Medicine, Baltimore, MD
⁴Department of Pediatrics, Division of Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX
⁵Department of Pediatrics, Baylor College of Medicine TX Children's Cancer Center, Houston, TX
⁶Cancer Center and Division of Pediatric Hematology/Oncology, Texas Children's Hospital, Houston, TX

4128

Role of Glucocorticoid Receptor in Normal and Malignant Germinal Center B Cells

Clarissa Corinaldesi¹^*, Antony Holmes, PhD, BSc, MSc¹^*, Elodie Bal, PhD¹^*, Zeinab Amini-Farsani, PhD¹^*, Govind Bhagat, MD², Laura Pasqualucci, MD¹, Katia Basso, PhD¹^* and Riccardo Dalla-Favera, MD¹^*

¹Institute for Cancer Genetics, Columbia University, New York, NY
²Department of Pathology & Cell Biology, Columbia University, New York, NY

4129

Developing a Pediatric-Relevant Murine MLL-r B-ALL Model to Study Factors Involved in Lineage Switching

Wenjuan Liao¹, Tian Liu¹^*, Julian Grandvallet Contreras, BS¹^*, Lynn Heltemes Harris, PhD²^*, Tzu Phang, PhD¹^*, Michael A. Farrar, PhD², M. Eric Kohler, MD, Ph.D³, Terry J Fry, MD^4,5 and Patricia Ernst, PhD^1,6

¹Department of Pediatrics, Section of Hematology/Oncology/BMT, University of Colorado Anschutz Medical Campus, Aurora, CO
²Center for Immunology and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
³Department of Pediatrics-Hematology, Oncology, and BMT, University of Colorado Anschutz Medical Campus, Aurora, CO
⁴Department of Pediatrics- Hematology, Oncology, and Bone Marrow Transplant, University of Colorado Anschutz Medical Campus, Aurora, CO
⁵Immunology Department and HI3 Initiative, University of Colorado Anschutz Medical Campus, Aurora, CO
⁶Pharmacology Department, University to University of Colorado Anschutz Medical Campus, Aurora, CO

4130

Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma

Eugenio Morelli, MD^1,2,3, Anil Aktas-Samur, PhD^3,4^*, Domenico Maisano, PhD, MSc^3,4^*, Claire Gao, BS⁴^*, Vanessa Favasuli, PhD⁴^*, Dimitrios Papaioannou, MD⁵, Na Liu, MS⁴^*, Marcello Turi, PhD¹^*, Pietro Folino, M.Sc⁶^*, Laure Vreux, Ph.D.^7,8^*, Michela Cumerlato, MS⁴^*, Liang Cheng, MS⁷^*, Iannis Aifantis, PhD⁹, Mariateresa Fulciniti, PhD⁴, Kenneth C. Anderson, MD¹⁰, Annamaria Gulla, MD¹, Mehmet K. Samur, PhD⁴ and Nikhil C. Munshi, MD⁴

¹Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy
²Department of Medical Oncology, University of Turin, Turin, Italy
³equally contributed, #, Italy
⁴Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
⁵Perlmutter Cancer Center, Department of Medicine, Division of Hematology/Oncology, NYU Grossman School of Medicine, New York, NY, New York, NY
⁶Dana Farber Cancer Institute, Boston, MA
⁷Medical Oncology, Dana-Farber Cancer Institute, Boston
⁸Harvard Medical School, Boston
⁹Department of Pathology, NYU Grossman School of Medicine, New York, NY
¹⁰Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

4131

Crispri Essentiality Screen Reveals the Essential Enhancers and Oncogenes Comprising the “Regulome” of the Notch-Collaborating Transcription Factor ETS1 in Human T-ALL

Karena Hsijan Lin¹^*, Annie Wang²^*, Kailey Lashbrook²^*, Kaitlyn Chan²^*, Elizabeth Choe³^*, Ashwin Iyer⁴^*, Kelly R. Barnett, PhD⁵^*, Daniel Savic, PhD⁵, Russell J. H. Ryan, MD⁶ and Mark Chiang, MD, PhD³

¹Cellular and Molecular Biology, University of Michigan, Ann Arbor, MI
²University of Michigan, Ann Arbor
³University of Michigan, Ann Arbor, MI
⁴Regeneron Pharmaceuticals, Tarrytown, NY
⁵St. Jude Children's Research Hospital, Memphis, TN
⁶Department of Pathology, University of Michigan Medical School, Ann Arbor, MI

4132

Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Giulia Calabretto^1,2,3^*, Elena Buson³^*, Zachary Hutchins¹^*, Colleen Isabelle⁴, Sydnee Scozzafava¹^*, Valentina Trimarco²^*, Barbara Mariotti⁵^*, Rachel Burzinski¹^*, Amy Boles¹^*, Elisa Rampazzo^2,3^*, Antonella Teramo^2,3^*, Sabrina Manni^2,3^*, Monica Facco^2,3^*, Gregorio Barilà⁶^*, Flavia Bazzoni⁵^*, Gianpietro Semenzato³^*, Livio Trentin², Jonathan E. Brammer⁷, Renato Zambello^2,3^* and Anjali Mishra¹

¹Thomas Jefferson University, Sydney Kimmel Cancer Center, Philadelphia, PA
²Department of Medicine, Hematology and Clinical Immunology section, Padua University School of Medicine, Padova, Italy
³Veneto Institute of Molecular Medicine (VIMM), Padova, Italy
⁴Thomas Jefferson University, Philadelphia, PA
⁵Department of Medicine, Division of General Pathology, University of Verona, Verona, Italy
⁶Hematology Unit, Ospedale San Bortolo, Vicenza, Italy
⁷Division of Hematology, The Ohio State University, Columbus, OH

4133

Deciphering Drivers of Functional and Phenotypic Changes through Genome-Wide Screen (DRIVE-Genome) to Identify Genes Inducing Genomic Instability in Myeloma

Srikanth Talluri, PhD^1,2^*, Leutz Buon, MS¹^*, Jiangning Zhao, MD, PhD¹^*, Daniel Meglino, BS¹^*, Chandraditya Chakraborty, PhD¹^*, Chengcheng Liao, MD, PhD¹^*, Mehmet K. Samur, PhD¹, David E. Root, PhD³^*, Masood A. Shammas, PhD^1,2^* and Nikhil C. Munshi, MD^2,4

¹Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
²VA Boston Healthcare System, Boston, MA
³Broad Institute of MIT and Harvard, Cambridge, MA
⁴Dana Farber Cancer Institute, The Jerome Lipper Myeloma Center, Boston, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH